Early versus delayed treatment of relapsed ovarian cancer

The Lancet

Volumn 377, Issue 9763, 2011, Pages 380-381

  Rustin, Gordon ^a   Van Der Burg, Maria ^b   Griffin, Clare ^c   Qian, Wendi ^c   Swart, Ann Marie ^c  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; DOXORUBICIN;

CANCER RELAPSE; CANCER SURVIVAL; CANCER THERAPY; EARLY THERAPY; HUMAN; LETTER; MEDICAL PRACTICE; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); THERAPY DELAY; TREATMENT OUTCOME;

EID: 79251584663     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60126-8     Document Type: Letter

References (2)

1. RT Morris, BJ Monk Ovarian cancer: relevant therapy, not timing, is paramount Lancet 376 2010 1120 1122
2. GJS Rustin, MEL van der Burg, CL Griffin Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial Lancet 376 2010 1155 1163